Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Universal Health International Group Holding Ltd. ( (HK:2211) ).
Universal Health International reported interim results for the six months ended 31 December 2025 showing revenue of RMB266.8 million, down 39.5% year on year, as well as a 32.7% drop in gross profit to RMB47.4 million. Despite the top-line weakness, gross margin improved to 17.8%, and operating loss narrowed to RMB3.4 million, helped by reduced selling and marketing expenses.
Net loss for the period narrowed to RMB6.1 million from RMB7.7 million, and adjusted EBITDA turned positive at RMB3.3 million versus a loss a year earlier, indicating some operational improvement. However, finance income declined and finance costs rose, weighing on the bottom line, while the restated basic loss per share reflected the impact of a prior share consolidation on shareholders.
The most recent analyst rating on (HK:2211) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Universal Health International Group Holding Ltd. stock, see the HK:2211 Stock Forecast page.
More about Universal Health International Group Holding Ltd.
Universal Health International Group Holding Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the healthcare and pharmaceutical distribution sector. The group focuses on selling health-related products and services in mainland China, positioning itself within the broader medical and wellness supply chain.
Average Trading Volume: 3,719,156
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$72.96M
For detailed information about 2211 stock, go to TipRanks’ Stock Analysis page.